Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
barefootrunner - Do you know if the data to be presented on AMRN is new data? Or data from the Marine trial that was already public? Thanks . Tim
AMRN , added another 1000 . looking for at least $25. Need a little patience is all.
Investor100 , thanks for information in a form even I could understand.
Yea , looking for more CLSN shares and Oct. calls
I've been waiting to re-enter AMRN under $13 , but I may not happen now
I was hoping for a bigger spike in ACUR so I could buy July puts.
FDA announces approval of ACUR drug
If ACUR is approved , I'm looking for a huge spike and then a rundown .
appreciate your efforts Sheff and good luck to us both on FCSC.
any thoughts if ttnp goes under $2.00?
where do you see NEOP going tomorrow?
Good time I believe to buy some more fcsc
time to add to fcsc ?
XNXSXX - thanks , it looks logical to me.
investor100 - I see it's under the 50 and 200 MA. Where do you see it going short term ? I have a huge position in terms of percentage of my portfolio , but I'm not worried that any "bad" news has leaked. I think the general market being overbought and the recent FDA actions (PLX) has investors a bit spooked . I will continue to buy on weakness and if I'm wrong I'll pay the price , but I see the risk/reward of AMRN to be excellent.
" Chart wise, AMRN is still looking bearish in the short term "..................Looking to buy more April 9 calls on any weakness.
" wouldnt that mean with stellar results that AMRN should be more like a $50-$100 stock? "................. First of all , it would take considerable time to ramp sales to that point and second , they will sell the company to a big drug company long before that time. Still I could see 200 to 300 % profit in this stock in a relative short time period. I made $30,000 on the first trial and plan to make even more this time. AMRN and EXAS are by far my favorite picks , simply because they lack the safety issues of most biotechs and their market potentials are HUGE !
Might be close to a good short at this point.
anyone interested in OPTR ?
Does NEOP now have a new symbol?
I'm also looking for higher prices for plx. I hold March $10 calls.
nywest329 = wow! great post. I"m WAY overweighted AMRN.
looking for $12 in AMRN by decision date.
AMRN is a huge portion of my portfolio. Although down from the high , I'm still way up. I like biotech stocks like AMRN and EXAS that has a very low safety profile.
Thinking of Jan 12 5s @ 1.10 options on AVNR. Any opinions?
from today...
Good news for both companies.
MDxHealth Licensee Exact Sciences Confirms Use of Biomarker and Methylation Technology in its Advanced Colon Cancer Test
DURHAM, NC, and LIEGE, BELGIUM – January 10, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that Exact Sciences (Nasdaq: EXAS) has confirmed that it is using an MDxHealth methylation biomarker together with MDxHealth’s methylation specific PCR (MSP) platform in Cologuard™, a non-invasive stool-based DNA colon cancer screening test. This confirmation has triggered a milestone payment to MDxHealth from Exact Sciences. MDxHealth will also receive royalties on net sales once the test is commercialized. Under the terms of a licensing agreement announced in August 2010, Exact Sciences has been evaluating several MDxHealth methylation biomarkers, among other markers, as well as the MSP technology in studies with its stool-based colon cancer test.
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company’s tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research centers such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders. Rating :
(4 Ratings)
EXAS up 9.62% today http://www.oncomethylome.com/news/press-...
Does anyone have a good idea for a entry point into ANX now the dilution has been announced ? Thanks.
AMRN down today on Zacks down grade based on "earnings" . Good buying opportunity in my opinion. Bought more at 7.59. Now have 6k.
Hi , anyone following ANIK for 2011 ?